$PPCB
Propanc Biopharma Inc Stock $ppcb

$ppcb Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223040980 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$324.0K	$401.0K	$471.5K
YoY Change	-39.22%	-14.96%	7.29%
% of Gross Profit
Research & Development	$114.0K	$16.24K	$101.3K
YoY Change	52.28%	-83.97%	117.67%
% of Gross Profit
Depreciation & Amortization	$114.00	$134.00	$473.00
YoY Change	-72.99%	-71.67%	-7.25%
% of Gross Profit
Operating Expenses	$438.1K	$417.2K	$572.8K
YoY Change	-27.95%	-27.17%	17.86%
Operating Profit	-$438.1K	-$417.2K	-$572.8K
YoY Change	-27.95%	-27.17%	17.86%
Interest Expense	$264.5K	$178.2K	$162.8K
YoY Change	168.17%	9.51%	-3622.77%
% of Operating Profit
Other Income/Expense, Net	-$274.9K	$66.35K	-$44.47K
YoY Change	3982.26%	-249.23%	860.78%
Pretax Income	-$713.0K	-$350.9K	-$617.3K
YoY Change	15.98%	-43.16%	25.81%
Income Tax	-$128.6K
% Of Pretax Income
Net Earnings	-$584.4K	-$350.9K	-$617.3K
YoY Change	20.39%	-43.16%	25.81%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.03	-$0.04	$0.00
Diluted Earnings Per Share	-$0.03	-$0.04	-$1.303K
COMMON SHARES
Basic Shares Outstanding	22.26M shares	14.83M shares	677.2M shares
Diluted Shares Outstanding	23.81M shares	10.99M shares	473.6K shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$71.65K	$6.630K	$19.40K
YoY Change	192.69%	-65.82%	-57.66%
Cash & Equivalents	$71.65K	$6.625K	$19.40K
Short-Term Investments
Other Short-Term Assets	$135.3K	$136.6K	$15.77K
YoY Change	436.57%	765.88%	88.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$210.8K	$145.8K	$37.86K
YoY Change	288.79%	285.09%	-32.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$50.00	$160.00	$1.437K
YoY Change	-95.38%	-88.87%	-59.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.040K	$1.930K	$1.930K
YoY Change	0.0%	0.0%	-10.65%
Total Long-Term Assets	$31.08K	$34.57K	$56.39K
YoY Change	-42.22%	-38.7%	879.03%
TOTAL ASSETS
Total Short-Term Assets	$210.8K	$145.8K	$37.86K
Total Long-Term Assets	$31.08K	$34.57K	$56.39K
Total Assets	$241.9K	$180.4K	$94.25K
YoY Change	123.94%	91.37%	51.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.158M	$1.081M	$899.2K
YoY Change	26.59%	20.25%	8.84%
Accrued Expenses	$1.337M	$1.215M	$860.4K
YoY Change	15.7%	41.22%	5.65%
Deferred Revenue
YoY Change
Short-Term Debt	$951.8K	$636.3K	$961.2K
YoY Change	15.82%	-33.81%	50.67%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.762M	$3.133M	$2.822M
YoY Change	25.72%	11.01%	19.15%
LONG-TERM LIABILITIES
Long-Term Debt	$35.21K	$23.37K	$0.00
YoY Change
Other Long-Term Liabilities	$8.040K	$13.15K	$39.36K
YoY Change	-73.97%	-66.59%
Total Long-Term Liabilities	$43.26K	$36.52K	$39.36K
YoY Change	40.05%	-7.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.762M	$3.133M	$2.822M
Total Long-Term Liabilities	$43.26K	$36.52K	$39.36K
Total Liabilities	$3.806M	$3.170M	$2.862M
YoY Change	25.87%	10.76%	20.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$65.80M	-$65.18M	-$62.56M
YoY Change	4.33%	4.18%
Common Stock	$36.17K	$14.83K	$677.2K
YoY Change	-97.1%	-97.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$46.48K	$46.48K	$46.48K
YoY Change	0.0%	0.0%
Treasury Stock Shares			1.000 shares
Shareholders Equity	-$3.564M	-$2.989M	-$2.768M
YoY Change
Total Liabilities & Shareholders Equity	$241.9K	$180.4K	$94.25K
YoY Change	123.94%	91.37%	51.61%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$584.4K	-$350.9K	-$617.3K
YoY Change	20.39%	-43.16%	25.81%
Depreciation, Depletion And Amortization	$114.00	$134.00	$473.00
YoY Change	-72.99%	-71.67%	-7.25%
Cash From Operating Activities	-$238.9K	-$333.5K	-$509.3K
YoY Change	6.07%	-34.53%	4.63%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	273.9K	$350.3K	$494.2K
YoY Change	9.57%	-29.11%	13.61%
NET CHANGE
Cash From Operating Activities	-238.9K	-$333.5K	-$509.3K
Cash From Investing Activities
Cash From Financing Activities	273.9K	$350.3K	$494.2K
Net Change In Cash	35.05K	-$3.422K	$15.33K
YoY Change	41.44%	-122.32%	-129.62%
FREE CASH FLOW
Cash From Operating Activities	-$238.9K	-$333.5K	-$509.3K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	PPCB	Deemed Dividend Upon Alternate Cashless Exercise Of Warrants DeemedDividendUponAlternateCashlessExerciseOfWarrants		usd
CY2023Q3	dei	Amendment Flag AmendmentFlag	false
CY2023Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2023Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q3	dei	Entity Central Index Key EntityCentralIndexKey	0001517681
CY2023Q2	PPCB	Refundable Advance Deposit RefundableAdvanceDeposit		usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2023Q3	us-gaap	Revenues Revenues		usd
CY2022Q3	PPCB	Derivative Expense DerivativeExpense		usd
CY2023Q3	PPCB	Gain From Settlement Of Accounts Payable GainFromSettlementOfAccountsPayable		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	PPCB	Issuance Of Common Stock For Issuable Shares IssuanceOfCommonStockForIssuableShares		usd
CY2022Q3	PPCB	Stock Issued During Period Value Of Common Stock For Alternate Cashless Exercise Of Warrants StockIssuedDuringPeriodValueOfCommonStockForAlternateCashlessExerciseOfWarrants		usd
CY2023Q3	PPCB	Stock Issued During Period Value Of Common Stock For Alternate Cashless Exercise Of Warrants StockIssuedDuringPeriodValueOfCommonStockForAlternateCashlessExerciseOfWarrants		usd
CY2023Q3	PPCB	Issuance Of Common Stock For Issuable Shares IssuanceOfCommonStockForIssuableShares		usd
CY2023Q3	PPCB	Deemed Dividend Upon Alternate Cashless Exercise Of Warrants DeemedDividendUponAlternateCashlessExerciseOfWarrants		usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2022Q3	PPCB	Derivative Expense DerivativeExpense		usd
CY2023Q3	PPCB	Gain From Settlement Of Accounts Payable GainFromSettlementOfAccountsPayable		usd
CY2022Q3	us-gaap	Other Noncash Expense OtherNoncashExpense		usd
CY2022Q3	PPCB	Increase Decrease In Refundable Advance Deposit IncreaseDecreaseInRefundableAdvanceDeposit		usd
CY2022Q3	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022Q3	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022Q3	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2023Q3	PPCB	Collection Of Subscription Receivable CollectionOfSubscriptionReceivable		usd
CY2023Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q3	PPCB	Relative Fair Value Of Warrant Granted In Connections With Loan Payable Related Party RelativeFairValueOfWarrantGrantedInConnectionsWithLoanPayableRelatedParty		usd
CY2023Q3	PPCB	Non Cash Warrant Grant For Settlement Of Accounts Payable NonCashWarrantGrantForSettlementOfAccountsPayable		usd
CY2023Q3	PPCB	Warrants Issued For Accrued Services WarrantsIssuedForAccruedServices		usd
CY2023Q2	PPCB	Refundable Advance Deposit RefundableAdvanceDeposit		usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023Q3	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExercised
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2023Q3	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Forfeited ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceForfeited
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2023Q3	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceExpired
CY2023Q3	PPCB	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Equity Instruments Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsEquityInstrumentsAggregateIntrinsicValueOutstanding		usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2023Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q3	dei	Document Type DocumentType	10-Q
CY2023Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q3	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
CY2023Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q3	dei	Entity File Number EntityFileNumber	000-54878
CY2023Q3	dei	Entity Registrant Name EntityRegistrantName	PROPANC BIOPHARMA, INC.
CY2023Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-0662986
CY2023Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	302
CY2023Q3	dei	Entity Address Address Line2 EntityAddressAddressLine2	6 Butler Street
CY2023Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Camberwell, VIC
CY2023Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	3124
CY2023Q3	dei	Entity Address Country EntityAddressCountry	AU
CY2023Q3	dei	City Area Code CityAreaCode	+61-03
CY2023Q3	dei	Local Phone Number LocalPhoneNumber	9882-0780
CY2023Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q3	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22258941	shares
CY2023Q3	us-gaap	Cash Cash	6625	usd
CY2023Q2	us-gaap	Cash Cash	10047	usd
CY2023Q3	PPCB	Goods And Services Tax Receivable Current GoodsAndServicesTaxReceivableCurrent	2634	usd
CY2023Q2	PPCB	Goods And Services Tax Receivable Current GoodsAndServicesTaxReceivableCurrent	2867	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20376	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6125	usd
CY2023Q3	PPCB	Refundable Advance Deposit RefundableAdvanceDeposit	116169	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	145804	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	19039	usd
CY2023Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1928	usd
CY2023Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1999	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	160	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	302	usd
CY2023Q3	us-gaap	Assets Assets	180371	usd
CY2023Q2	us-gaap	Assets Assets	60328	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1081316	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	966718	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	614870	usd
CY2023Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	579707	usd
CY2023Q3	us-gaap	Interest Payable Current InterestPayableCurrent	52743	usd
CY2023Q2	us-gaap	Interest Payable Current InterestPayableCurrent	44709	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	126000	usd
CY2023Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	397443	usd
CY2023Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	390539	usd
CY2023Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	119069	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	423209	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	579083	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	587618	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3133113	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3158229	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	36517	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	19278	usd
CY2023Q3	us-gaap	Liabilities Liabilities	3169630	usd
CY2023Q2	us-gaap	Liabilities Liabilities	3177507	usd
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500005	shares
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500005	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14833210	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14833210	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6031250	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6031250	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	14833	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	6031	usd
CY2023Q3	PPCB	Common Stock Issuable Shares CommonStockIssuableShares	626229	shares
CY2023Q2	PPCB	Common Stock Issuable Shares CommonStockIssuableShares	1621653	shares
CY2023Q3	PPCB	Common Stock Issuable CommonStockIssuable	626	usd
CY2023Q2	PPCB	Common Stock Issuable CommonStockIssuable	1621	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60851382	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60311502	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1368550	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1294876	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65178173	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64684732	usd
CY2023Q3	PPCB	Treasury Stock Price Per Share TreasuryStockPricePerShare	0.001
CY2023Q2	PPCB	Treasury Stock Price Per Share TreasuryStockPricePerShare	0.001
CY2023Q3	us-gaap	Treasury Stock Value TreasuryStockValue	46477	usd
CY2023Q2	us-gaap	Treasury Stock Value TreasuryStockValue	46477	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-2989259	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3117179	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	180371	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	60328	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	393828	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	465132	usd
CY2023Q3	us-gaap	Occupancy Net OccupancyNet	7149	usd
CY2022Q3	us-gaap	Occupancy Net OccupancyNet	6373	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16242	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	101325	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	417219	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	572830	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-417219	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-572830	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	178234	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	162752	usd
CY2023Q3	us-gaap	Interest Income Other InterestIncomeOther	17	usd
CY2022Q3	us-gaap	Interest Income Other InterestIncomeOther	2	usd
CY2023Q3	PPCB	Derivative Expense DerivativeExpense	77721	usd
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	303929	usd
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	65173	usd
CY2022Q3	PPCB	Gain From Settlement Of Accounts Payable GainFromSettlementOfAccountsPayable	17499	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	34310	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-610	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-15948	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	36223	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	66353	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-44465	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-350866	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-617295	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-350866	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-617295	usd
CY2023Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	142575	usd
CY2022Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	389235	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-493441	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1006530	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.13
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.13
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10989681	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10989681	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	473589	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	473589	shares
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-493441	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1006530	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	73674	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	126396	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	73674	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	126396	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-419767	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-880134	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3023649	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	48469	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	456939	usd
CY2022Q3	PPCB	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	100000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	133646	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2408	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	5551	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	126396	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-617295	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-2767535	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3117179	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3117179	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	229190	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	34838	usd
CY2023Q3	PPCB	Relative Fair Value Of Warrant Granted In Connection With Loan Payable Related Party RelativeFairValueOfWarrantGrantedInConnectionWithLoanPayableRelatedParty	141084	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	73674	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-350866	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-350866	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-2989259	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-2989259	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-350866	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-617295	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2408	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-15948	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	36223	usd
CY2023Q3	us-gaap	Depreciation Depreciation	134	usd
CY2022Q3	us-gaap	Depreciation Depreciation	473	usd
CY2023Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	69457	usd
CY2022Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	31275	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	5128	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	5131	usd
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	303929	usd
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	65173	usd
CY2023Q3	PPCB	Derivative Expense DerivativeExpense	77721	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	34310	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-610	usd
CY2022Q3	PPCB	Gain From Settlement Of Accounts Payable GainFromSettlementOfAccountsPayable	17499	usd
CY2023Q3	us-gaap	Other Noncash Expense OtherNoncashExpense	1437	usd
CY2023Q3	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-88846	usd
CY2022Q3	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-115769	usd
CY2023Q3	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-132	usd
CY2022Q3	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	523	usd
CY2023Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	14468	usd
CY2022Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7747	usd
CY2023Q3	PPCB	Increase Decrease In Refundable Advance Deposit IncreaseDecreaseInRefundableAdvanceDeposit	116169	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	148834	usd
CY2022Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	45121	usd
CY2023Q3	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	12275	usd
CY2022Q3	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	10415	usd
CY2023Q3	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	55693	usd
CY2022Q3	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	15162	usd
CY2023Q3	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	15712	usd
CY2022Q3	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	13430	usd
CY2023Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-5032	usd
CY2022Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4649	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-333457	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-509315	usd
CY2023Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	220000	usd
CY2022Q3	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	345750	usd
CY2023Q3	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	142909	usd
CY2022Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	24711	usd
CY2023Q3	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	120000	usd
CY2023Q3	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	153256	usd
CY2022Q3	PPCB	Collection Of Subscription Receivable CollectionOfSubscriptionReceivable	23758	usd
CY2022Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	100000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	350347	usd
CY2022Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	494219	usd
CY2023Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-20312	usd
CY2022Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	30425	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3422	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15329	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10047	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4067	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6625	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19396	usd
CY2023Q3	us-gaap	Interest Paid Net InterestPaidNet	2713	usd
CY2022Q3	us-gaap	Interest Paid Net InterestPaidNet	2277	usd
CY2023Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	34838	usd
CY2022Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	133646	usd
CY2023Q3	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	114131	usd
CY2022Q3	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	349530	usd
CY2023Q3	PPCB	Debt Discounts Related To Derivative Liability DebtDiscountsRelatedToDerivativeLiability	70000	usd
CY2022Q3	PPCB	Debt Discounts Related To Derivative Liability DebtDiscountsRelatedToDerivativeLiability	93668	usd
CY2023Q3	PPCB	Relative Fair Value Of Warrant Granted In Connections With Loan Payable Related Party RelativeFairValueOfWarrantGrantedInConnectionsWithLoanPayableRelatedParty	141084	usd
CY2022Q3	PPCB	Non Cash Warrant Grant For Settlement Of Accounts Payable NonCashWarrantGrantForSettlementOfAccountsPayable	23050	usd
CY2022Q3	PPCB	Warrants Issued For Accrued Services WarrantsIssuedForAccruedServices	5551	usd
CY2023Q3	PPCB	Deemed Dividend Upon Alternate Cashless Exercise Of Warrants1 DeemedDividendUponAlternateCashlessExerciseOfWarrants1	142575	usd
CY2022Q3	PPCB	Deemed Dividend Upon Alternate Cashless Exercise Of Warrants1 DeemedDividendUponAlternateCashlessExerciseOfWarrants1	389235	usd
CY2023Q2	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	one-for-one thousand (1:1,000)
CY2023Q3	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zvV3yvly14n" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_z2GydP8dOeJg">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PROPANC BIOPHARMA, INC. AND SUBSIDIARY</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>September 30, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>
CY2023Q3	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	0.6428	pure
CY2023Q2	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	0.6664	pure
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1294876	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	73674	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1368550	usd
CY2023Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q3	PPCB	Refundable Advance Deposit RefundableAdvanceDeposit	116169	usd
CY2023Q3	PPCB	Goods And Services Tax Receivable Current GoodsAndServicesTaxReceivableCurrent	2634	usd
CY2023Q2	PPCB	Goods And Services Tax Receivable Current GoodsAndServicesTaxReceivableCurrent	2867	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16242	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	101325	usd
CY2023Q3	us-gaap	Debt Instrument Convertible Terms Of Conversion Feature DebtInstrumentConvertibleTermsOfConversionFeature	Each holder of the notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ ability to increase such limitation to 9.99% upon 60 days’ notice to the Company), and each note may not be converted during the first six-month period from the date of issuance.
CY2023Q3	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	0.0499	pure
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11396197211.12	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10418785.12	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-350866	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-333457	usd
CY2023Q3	PPCB	Working Capital Deficit WorkingCapitalDeficit	2987309	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-2989259	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-65178173	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24532	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25432	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	24372	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	25130	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	160	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	302	usd
CY2023Q3	us-gaap	Depreciation Depreciation	134	usd
CY2022Q3	us-gaap	Depreciation Depreciation	473	usd
CY2023Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.10	pure
CY2023Q3	PPCB	Proceeds From Loan Payable Related Party ProceedsFromLoanPayableRelatedParty	153256	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	126000	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	331500	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	338362	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	79236	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	38994	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	145179	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	91171	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	397443	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	390539	usd
CY2023Q3	PPCB	Debt Instrument Debt Default Interest Rate DebtInstrumentDebtDefaultInterestRate	0.24	pure
CY2023Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	34838	usd
CY2022Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	133646	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2022Q2	PPCB	Number Of Preferred Stock Authorized Shares NumberOfPreferredStockAuthorizedShares	1500005	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	3001500005	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10000000000	shares
CY2022Q3	PPCB	Number Of Preferred Stock Authorized Shares NumberOfPreferredStockAuthorizedShares	1500005	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	10001500005	shares
CY2023Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	one-for-one thousand (1:1,000)
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500005	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	70800	usd
CY2023Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	5184	usd
CY2023Q3	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	1437	usd
CY2023Q3	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	113622	usd
CY2023Q3	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	147932	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	34310	usd
CY2023Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	34838	usd
CY2023Q3	PPCB	Deemed Dividend DeemedDividend	142575	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	3396	shares
CY2023Q2	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding	5440
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	15000000	shares
CY2023Q3	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Price Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAveragePriceIssued	0.01
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	15003396	shares
CY2023Q3	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageOutstanding	1.24
CY2023Q3	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	15003378	shares
CY2023Q3	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisable	1.24
CY2023Q3	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instruments Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerms	P2Y9M3D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	15003396	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	15003396	shares
CY2023Q3	PPCB	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	15003378	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0.059	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4533000
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0.059	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4533000
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	0.059	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4533000
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y7M13D
CY2023Q3	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2023Q3	PPCB	Penalty Amount PenaltyAmount	30000	usd
CY2020Q4	PPCB	Royalties Percentage RoyaltiesPercentage	0.02	pure
CY2023Q3	PPCB	Unreimbursed Lab Fees UnreimbursedLabFees	24446	usd
CY2023Q2	PPCB	Unreimbursed Lab Fees UnreimbursedLabFees	18056	usd
CY2023Q3	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2023	us-gaap	Royalty Expense RoyaltyExpense	0	usd
CY2022Q2	PPCB	Incremental Borrowing Rate IncrementalBorrowingRate	0.08	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	17356	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	19284	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2333	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	34307	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M7D
CY2023Q3	us-gaap	Payments For Rent PaymentsForRent	7149	usd
CY2022Q3	us-gaap	Payments For Rent PaymentsForRent	6373	usd
CY2022	PPCB	Bonus Payable BonusPayable	144166	aud
CY2022	PPCB	Bonus Payable BonusPayable	99691	usd
CY2023	PPCB	Bonus Payable BonusPayable	73387	aud
CY2023	PPCB	Bonus Payable BonusPayable	48905	usd
CY2023Q3	PPCB	Bonus Payable BonusPayable	25000	aud
CY2023Q3	PPCB	Bonus Payable BonusPayable	16070	usd
CY2023Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	107500	aud
CY2023Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	69101	usd
CY2023Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	96000	aud
CY2023Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	64627	usd
CY2023Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	34500	usd
CY2022Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	33750	usd
CY2023Q3	us-gaap	Share Price SharePrice	0.024
CY2023Q3	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	119069	usd
CY2023Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	119069	usd
CY2023Q2	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	423209	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	423209	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	423209	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	423209	usd
CY2023Q3	us-gaap	Embedded Derivative Gain On Embedded Derivative EmbeddedDerivativeGainOnEmbeddedDerivative	70000	usd
CY2023Q3	us-gaap	Embedded Derivative Loss On Embedded Derivative EmbeddedDerivativeLossOnEmbeddedDerivative	77721	usd
CY2023Q3	PPCB	Reduction Of Derivative Liability Upon Debt Conversion ReductionOfDerivativeLiabilityUponDebtConversion	-147932	usd
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	303929	usd
CY2023Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	119069	usd
CY2023Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	119069	usd

Files In Submission

Name	View Source	Status
0001493152-23-040980-index-headers.html	Edgar Link	pending
0001493152-23-040980-index.html	Edgar Link	pending
0001493152-23-040980.txt	Edgar Link	pending
0001493152-23-040980-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ppcb-20230930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
ppcb-20230930_cal.xml	Edgar Link	unprocessable
ppcb-20230930_def.xml	Edgar Link	unprocessable
ppcb-20230930_lab.xml	Edgar Link	unprocessable
ppcb-20230930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PPCB
Propanc Biopharma Inc Stock $ppcb

2023 Q4 Form 10-Q Financial Statement

#000149315223040980 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PPCB Propanc Biopharma Inc Stock $ppcb

2023 Q4 Form 10-Q Financial Statement

#000149315223040980 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PPCB
Propanc Biopharma Inc Stock $ppcb